Hepatic steatosis is a predictor of poor response to interferon alpha-2b and ribavirin combination therapy in Japanese patients with chronic hepatitis C.

[1]  C. Sabin,et al.  Insulin Resistance Plays a Significant Role in Liver Fibrosis in Chronic Hepatitis C and in the Response to Antiviral Therapy , 2005, The American Journal of Gastroenterology.

[2]  B. Neuschwander‐Tetri,et al.  Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  Yoshiyuki Suzuki,et al.  Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN‐resistant cases with hepatocyte steatosis , 2005, Journal of medical virology.

[4]  R. Andrade,et al.  Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. , 2005, Gastroenterology.

[5]  N. Zein.  Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. , 2005, Journal of hepatology.

[6]  D. Dimitropoulou,et al.  Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C , 2005, European journal of gastroenterology & hepatology.

[7]  O. Chazouilleres,et al.  Impact of steatosis on progression of fibrosis in patients with mild hepatitis C , 2005, Hepatology.

[8]  A. Sanyal,et al.  Hepatitis C and nonalcoholic fatty liver disease. , 2004, Seminars in liver disease.

[9]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[10]  J. McHutchison,et al.  The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. , 2004, Journal of hepatology.

[11]  L. Rubbia‐Brandt,et al.  Steatosis affects chronic hepatitis C progression in a genotype specific way , 2004, Gut.

[12]  A. Lonardo,et al.  Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. , 2004, Gastroenterology.

[13]  A. Greenberg,et al.  Adipocytokines and insulin resistance. , 2004, The Journal of clinical endocrinology and metabolism.

[14]  S. Kihara,et al.  Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. , 2003, Gastroenterology.

[15]  R. Stravitz,et al.  Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome , 2003, American Journal of Gastroenterology.

[16]  M. Manns,et al.  Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C , 2003, Hepatology.

[17]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.

[18]  J. McHutchison,et al.  The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C , 2003, Journal of viral hepatitis.

[19]  L. Seeff,et al.  Natural history of chronic hepatitis C , 2002, Hepatology.

[20]  Y. Takei,et al.  Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. , 2002, Gastroenterology.

[21]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[22]  M. Gambardella,et al.  Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity , 2001, Hepatology.

[23]  K. Abid,et al.  Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. , 2000, Journal of hepatology.

[24]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[25]  K Koike,et al.  Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. , 1997, The Journal of general virology.

[26]  M. Kohara,et al.  Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Takao Tsuji,et al.  New Inuyama classification; new criteria for histological assessment of chronic hepatitis , 1996 .

[28]  E. Larrea,et al.  Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C , 1996 .

[29]  M. Onji,et al.  Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.

[31]  E. Esrailian,et al.  Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. , 2004, Journal of hepatology.

[32]  Y. Jeong,et al.  Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection , 2003 .